98%
921
2 minutes
20
The hypothalamus, which consists of histologically and functionally distinct subunits, primarily modulates vegetative symptoms in major depressive disorder (MDD). Sex differences in MDD have been well-documented in terms of illness incidence rates and symptom profiles. However, few studies have explored subunit-level and sex-specific anatomic differences in the hypothalamus in MDD compared to healthy controls (HCs). High-resolution 3D T1-weighted images were obtained from 133 treatment-naïve patients with MDD and 130 age-, sex-, education years-, and handedness-matched HCs. MRI data were preprocessed and segmented into ten bilateral hypothalamic subunits with FreeSurfer software. We tested for both common and sex-specific patterns of hypothalamic anatomic differences in MDD. Regardless of sex, patients with MDD showed significantly smaller volumes in the left anterior-inferior subunit (a-iHyp) and larger volumes in the right posterior subunit (posHyp). The volumes of the left a-iHyp were negatively correlated with sleep disturbance scores in the MDD group. A significant sex-by-diagnosis interaction was observed in the right whole hypothalamus, and subsequent post-hoc analyses revealed that males with MDD showed significantly larger volumes, while females with MDD showed significantly smaller volumes relative to their sex-matched HCs. Common differences in MDD were found in the left anterior-inferior and right posterior hypothalamus that are involved in regulating circadian rhythms and reward, while sex-specific differences in MDD were observed in the right whole hypothalamus. These findings enhance our understanding of distinct hypothalamic subunit related to MDD and shed light on the neurobiology underlying sex-related variations in MDD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00429-025-02904-w | DOI Listing |
J Affect Disord
September 2025
Department of Psychiatry, The Affiliated Kangning Hospital of Ningbo University, Ningbo Kangning Hospital, Ningbo, China; Medical Center, Ningbo University, Ningbo, China. Electronic address:
Objective: This study aimed to identify potential mutations associated with major depressive disorder (MDD) and evaluate disease-associated risk factors.
Methods: Total genomic DNAwas extracted from the participants' blood samples, and the complete mitochondrial genome wasamplified by PCR, purified, and sequenced. Mutation burden analysis and functional mutation analysis was performed, including total mutation counts, highly conserved mutations (Conservation Index >75 %), and structurally disruptive mutations.
J Affect Disord
September 2025
Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea; Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; D
Background: Major depressive disorder (MDD), anxiety disorders, and self-harm are substantial contributors to the global disease burden, exacerbated by the COVID-19 pandemic.
Methods: We used Global Burden of Diseases Study (GBD) 2021 to estimate global, regional, and national prevalence, mortality, and disability-adjusted life years (DALYs) for MDD, anxiety disorders, and self-harm from 1990 to 2021. Annual percentage changes were calculated for pre-pandemic (1990-2019) and pandemic (2019-2021) periods.
J Affect Disord
September 2025
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, SE5 9RT, UK; National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College Lond
Although inflammation has been suggested as a promising therapeutic target for major depressive disorder (MDD), uncertainty remains about how to recognise individuals who may benefit from anti-inflammatory treatments. Transcriptomic profiles provide an important tool to identify relevant biological mechanisms associated with response. In this study, we investigate: i) the ability of transcriptomic profiles to predict antidepressant response to anti-inflammatory treatment with minocycline, and ii) the effect of minocycline on transcriptomic profiles based on the antidepressant response.
View Article and Find Full Text PDFJ Affect Disord
September 2025
Department of Psychiatry, University of North Carolina at Chapel Hill, United States of America.
Background: Perimenopausal onset depression (PO-MDD) is a common cause of distress and functional impairment, though efforts to describe its clinical symptomatology have been limited. We aimed to characterize affective and anxiety symptoms associated with PO-MDD, and to identify clinical correlates of distress, including anxiety, temperament and climacteric symptoms.
Methods: Baseline data from unmedicated women, ages 44-55, with PO-MDD (n = 49) and without PO-MDD (controls; n = 37) in the late-perimenopause (STRAW -1 criteria) recruited for two studies examining estrogen's effect on brain activation were included.
Introduction: Major depressive disorder (MDD) represents a critical public health issue, impacting millions globally and significantly contributing to disability-adjusted life years (DALYs). Major Depressive Episode (MDE) is a feature of MDD characterized by severe depressive symptoms. The role of glutamate, a primary excitatory neurotransmitter, in MDD has been extensively studied and several drugs improving MDE/MDD impact the glutamate cascade; however, findings regarding blood glutamate levels in patients with a current MDE in a context of MDD remain inconsistent.
View Article and Find Full Text PDF